Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients

Taros Chemicals and Welab Barcelona partner for drug Discovery and development services

The combination will support clients in getting their end-to-end discovery and development programs delivered.

Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Zydus receives final approval from the USFDA for Acetazolamide Tablets

Acetazolamide is used to treat glaucoma

Bridgewest Group launches new sterile injectable CDMO NovaCina

SK Capital completes acquisition of Apotex

TSCS team met All India Imam Organization Chief to discuss on thalassemia eradication in India

Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease